ロード中...
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
PURPOSE: Subregional hypoxia is a common feature of tumors and is recognized as a limiting factor for the success of radiotherapy and chemotherapy. TH-302, a hypoxia-activated prodrug selectively targeting hypoxic regions of solid tumors, delivers a cytotoxic warhead to the tumor, while maintaining...
保存先:
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3985381/ https://ncbi.nlm.nih.gov/pubmed/22382881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-012-1852-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|